Macular degeneration agents
(Redirected from Aflibercept)
Macular degeneration is an age-related condition that affects the retina, leading to a progressive decline in central visual acuity. The disease is largely linked to neovascularization in the subretinal space, with vascular endothelial growth factor (VEGF) playing a significant role. In response, various agents have been formulated to target VEGF, effectively slowing the progression of the neovascular or "wet" form of macular degeneration.
Mechanism of Action
The vascularization in macular degeneration is believed to be driven, at least in part, by the action of VEGF. Therefore, drugs that specifically inhibit VEGF have been shown to be effective in treating the wet form of the condition.
List of Macular Degeneration Agents
Several therapeutic agents are used in the treatment of macular degeneration. They can be classified as follows:
- Monoclonal antibodies to VEGF: bevacizumab, ranibizumab
- Aptamers: pegaptanib
- Fusion VEGF receptor proteins: aflibercept
All these agents are administered through intravitreal injections, typically every 4 to 8 weeks. Most of their side effects are ocular, often linked to the injection process. Systemic exposure is minimal, making ex-ocular adverse events rare. Notably, these agents have been linked to cardiovascular or cerebrovascular thromboembolic events, albeit rarely. None of these agents, when administered via intravitreal injection, have been implicated in hepatotoxicity.
Bevacizumab
- Brand Name: Avastin
- Description: Bevacizumab is a humanized monoclonal antibody that targets VEGF. While it is approved for intravenous use in various cancers, it has been employed off-label to treat macular degeneration. In clinical trials, its efficacy was found to be comparable to that of ranibizumab.
- Dosage: Off-label use for macular degeneration involves administering 1.25 mg (0.05 mL) once monthly via intravitreal injection.
Ranibizumab
- Brand Name: Lucentis
- Description: Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that targets VEGF. It has been approved for the treatment of neovascular (wet) age-related macular degeneration and other ocular conditions.
- Dosage: The advised dosage is 0.5 mg once monthly by intravitreal injection.
Pegaptanib
- Brand Name: Macugen
- Description: Pegaptanib is a pegylated aptamer, which binds with and neutralizes extracellular VEGF. It has received approval for treating neovascular (wet) age-related macular degeneration.
- Dosage: The recommended dosage is 0.3 mg administered via intravitreal injection once every six weeks.
Aflibercept
- Brand Name: Eylea
- Description: Aflibercept is a unique fusion protein that acts as a decoy receptor, competing for VEGF binding. It has been approved for a range of ocular conditions, including neovascular age-related macular degeneration.
- Dosage: Initially, 2 mg once monthly by intravitreal injection is recommended.
Note: Aflibercept is also available as ziv-aflibercept (Zaltrap) for parenteral use in metastatic colon cancer combined with other antineoplastic agents. The addition of ziv-aflibercept to this combination has not shown an increased risk of liver injury.
Conclusion
Macular degeneration agents have revolutionized the treatment of the wet form of the disease. By specifically targeting VEGF, they slow down the progression and offer improved quality of life to those affected. As with any medication, monitoring for side effects and understanding potential risks are essential.
Macular Degeneration Agents, Monoclonal Antibodies
Macular degeneration agents | ||||||||
---|---|---|---|---|---|---|---|---|
This macular degeneration related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD